Last reviewed · How we verify

NCT02337309

SF1126 for Patients With Relapsed or Refractory Neuroblastoma

Terminated Phase 1 Last updated 20 August 2018
What this trial tests

Phase 1 trial testing SF1126 in Neuroblastoma in 4 participants. Terminated before completion.

Timeline
9 July 2015
Primary endpoint
22 May 2018
22 May 2018

Quick facts

Lead sponsorNew Approaches to Neuroblastoma Therapy Consortium
PhasePhase 1
StatusTerminated
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment4
Start date9 July 2015
Primary completion22 May 2018
Estimated completion22 May 2018
Sites11 locations across United States

Drugs / interventions tested

Conditions studied

Sponsor

New Approaches to Neuroblastoma Therapy Consortium

Who can join

Adults 1 to 30, any sex, with Neuroblastoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

SF1126 is a novel inhibitor of PI3 kinase and mTOR that includes an active moiety (consisting of LY294002) linked to an RGDS tetrapeptide that targets the active agent to integrin expressing tissues. In this first pediatric phase 1 trial of SF1126, dose escalation will follow a 3+3 dose escalation design. Once a recommended phase 2 pediatric dose is identified, an expansion cohort of 10 patients with tumors with MYCN amplification, Mycn expression, or Myc expression will be treated. Funding Source - FDA OOPD

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Tumor biomarkers for diagnosis, prognosis and targeted therapy.
    Zhou Y, Tao L, Qiu J, Xu J, et al · · 2024 · cited 379× · PMID 38763973 · DOI 10.1038/s41392-024-01823-2
  2. Molecular targeting therapies for neuroblastoma: Progress and challenges.
    Zafar A, Wang W, Liu G, Wang X, et al · · 2021 · cited 291× · PMID 33155698 · DOI 10.1002/med.21750
  3. PI3K inhibitors in inflammation, autoimmunity and cancer.
    Stark AK, Sriskantharajah S, Hessel EM, Hessel EM, et al · · 2015 · cited 236× · PMID 26093105 · DOI 10.1016/j.coph.2015.05.017
  4. On-Target Anti-TGF-β Therapies Are Not Succeeding in Clinical Cancer Treatments: What Are Remaining Challenges?
    Teixeira AF, Ten Dijke P, Zhu HJ. · · 2020 · cited 159× · PMID 32733895 · DOI 10.3389/fcell.2020.00605
  5. Recent developments in epigenetic cancer therapeutics: clinical advancement and emerging trends.
    Nepali K, Liou JP. · · 2021 · cited 122× · PMID 33840388 · DOI 10.1186/s12929-021-00721-x
  6. Epigenetic polypharmacology: from combination therapy to multitargeted drugs.
    de Lera AR, Ganesan A. · · 2016 · cited 99× · PMID 27752293 · DOI 10.1186/s13148-016-0271-9
  7. Combinatorial Approach to Improve Cancer Immunotherapy: Rational Drug Design Strategy to Simultaneously Hit Multiple Targets to Kill Tumor Cells and to Activate the Immune System.
    Joshi S, Durden DL. · · 2019 · cited 76× · PMID 30853982 · DOI 10.1155/2019/5245034
  8. More than the genes, the tumor microenvironment in neuroblastoma.
    Borriello L, Seeger RC, Asgharzadeh S, DeClerck YA. · · 2016 · cited 61× · PMID 26597947 · DOI 10.1016/j.canlet.2015.11.017

Verify or expand the search:

Other trials of SF1126

Trials testing the same drug.

Other recruiting trials for Neuroblastoma

Currently open trials in the same condition.

Other New Approaches to Neuroblastoma Therapy Consortium trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02337309.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing